In this paper, we presents a novel hybrid method that improves brain tumor segmentation by integrating hemodynamic properties from dynamic susceptibility contrast (DSC) enhanced MRI with deep learning spatial segmentation techniques. The approach, tested on a cohort of 513 patients, demonstrated enhanced segmentation precision and the ability to uncover hemodynamic heterogeneity within tumors, showing potential for more accurate tumor monitoring and treatment response assessment..

This article explores the complex landscape of AI/ML applications in clinical trials, shedding light on regulatory challenges through the lens of FDA discussions, EMA reflections, and stakeholder feedback.

In this paper, we reviewed the recent development of Label-Free Chemically and Molecularly Selective Magnetic Resonance Imaging.